Catalog: | C-FC-4267A |
Product Type: | FCM Antibody |
Size: | 50 µL/100 µL |
Reactivity: | Human |
Specificity: | Human S100P |
Analysis mode: | FCM |
Host: | Rabbit |
Clonality: | Monoclonal |
Isotype: | IgG |
Alternate names: | S100 calcium binding protein P |
Form: | Liquid |
Shipping: | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Storage: | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Purification method: | Protein A |
Conjugation: | Unconjugated |
Immunogen: | Recombinant Human S100P Protein |
Buffer: | 0.2 μm filtered solution in PBS |
Application: | Calcium-binding Proteins and Related Molecules |
Protein S100-P, also known as Protein S100-E, S100 calcium-binding protein P, S100P and S100E, is a nucleus and cytoplasm protein that belongs to the S-100 family. S100P / S100E contains twoEF-hand domains. S100P protein regulates calcium signal transduction and mediates cytoskeletal interaction, protein phosphorylation and transcriptional control. S100P / S100E overexpression can upregulate androgen receptor expression and thereby promote prostate cancer progression by increasing cell growth. S100P / S100E may directly confer resistance to chemotherapy. S100P / S100E induction may be considered an important step in the initial stage of lung adenocarcinomas, whereas its downregulation in advanced stages seems to be important for tumour progression in which DNA methylation and/or feedback transcription processes play a critical role. S100P / S100E plays a major role in the aggressiveness of pancreatic cancer that is likely mediated by its ability to activate RAGE. Interference with S100P / S100E may provide a novel approach for treatment of pancreatic cancer. S100P / S100E could be considered a potential drug target or a chemosensitization target, and could also serve as a biomarker for aggressive, hormone-refractory and metastatic prostate cancer.
Copyright © 2025 Creative Biogene. All rights reserved.